IDEXX Laboratories, Inc. is a Delaware-incorporated company headquartered in Westbrook, Maine that develops, manufactures, and distributes diagnostic products and services for companion animal, livestock, and poultry health, as well as water and dairy quality testing. The company trades on the NASDAQ Global Select Market under the ticker IDXX. IDEXX operates globally and files annual reports on Form 10-K with the SEC, with its most recent 10-K covering the fiscal year ended December 31, 2025.

What is IDXX's DredgeCap risk score?

DredgeCap's AI analysis rates IDXX at 2.5/10 on the risk scale — Low risk. This score reflects dilution exposure, debt toxicity, liquidity position, and going-concern posture as disclosed in SEC filings.

Does IDXX have a going concern warning?

No current auditor going-concern warning is flagged in IDXX's SEC filings. Risk assessment is based on other filing-disclosed factors.

When did IDXX last file with the SEC?

IDXX's most recent SEC filing was a 8-K filed 2026-03-26. All filings are available on SEC EDGAR.

← IDXX Overview

10-QMay 5, 2026· Quarter Ended March 31, 2026

IDXX — 10-Q Filing

Track IDXX for Alerts

IDXX 10-Q Summary

For the quarter ended March 31, 2026, Idexx Laboratories Inc /de reported revenue of $1.14B, up 14.3% year-over-year. Operating income was $362.6M, up 14.5% year-over-year; net income was $278.4M, up 14.7% year-over-year. The revenue mix shifted: Product revenue grew 16.2% to $666.1M, while Service revenue grew 11.6% to $474.7M.

IDXX Financial Highlights

Metric

Q-End 03/26

Q-End 03/25

Revenue

$1.14B

$998.4M

▲+14.3% YoY

Gross Profit

$722.7M

$623.4M

▲+15.9% YoY

Operating Income

$362.6M

$316.5M

▲+14.5% YoY

Net Income

$278.4M

$242.7M

▲+14.7% YoY

IDXX Revenue by Segment

Segment

Q-End 03/26

Q-End 03/25

Product revenue

$666.1M

$573.1M

▲+16.2% YoY

Service revenue

$474.7M

$425.4M

▲+11.6% YoY

IDXXWhat's Driving the Change

Depreciation & amortization

up 10.6% from $34.1M a year earlier

$37.7M

▲

Current DredgeCap Risk Profile

Risk Score

2.5/10

LOW

Dilution

1.5

Debt Toxicity

2.0

Going Concern

✓ Not flagged

The risk profile above reflects the latest cached DredgeCap analysis for IDXX. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open IDXX's company page.

What is a 10-Q?

A quarterly report covering the three months just ended. Includes unaudited condensed financial statements (balance sheet, income statement, cash flow), Management Discussion and Analysis (MD&A), and disclosure of material changes since the last annual report. Required for the first three fiscal quarters; the fourth quarter is rolled into the 10-K.

More on IDXX

Financial highlights are sourced directly from the 10-Q income statement (three months ended). YoY % compares to the same quarter one year earlier as reported by the issuer. Per-segment breakdown is extracted from the 10-Q revenue table; segments are shown in the order the issuer reports them. The plain-language summary above is composed mechanically from the filing's reported numbers — no analysis or opinion. Form-type explainers and 8-K item descriptions are derived from SEC documentation. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.